<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359395</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00045800</org_study_id>
    <nct_id>NCT03359395</nct_id>
  </id_info>
  <brief_title>Pre-medication With Alfentanil vs Placebo During ECT</brief_title>
  <official_title>Effects of Pre-medication With Alfentanil on Hemodynamics During and Immediately Following Electroconvulsive Therapy (ECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized
      with the administration of alfentanil as part of their anesthetic regimen. This study
      proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved
      drug used on a daily basis by anesthesiologists on other surgeries so this is not a new
      indication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electroconvulsive therapy is associated with brief hemodynamic alterations that in some
      patients may be well outside the range of normalcy and potentially dangerous to the patient
      (Duma A, et al). This cardiovascular response is caused by activation of the autonomic
      nervous system and consists of an initial parasympathetic response rapidly followed by
      sympathetically mediated tachycardia and hypertension. The ultra-short acting synthetic
      opioid alfentanil has a rapid onset and duration of action that mirrors the duration of
      hemodynamic perturbation associated with ECT while having minimal or no effect on the
      duration or quality of the seizure. This drug may be effective in blunting the hemodynamic
      perturbations associated with ECT with a minimal amount of side effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>study med prepared by a provider not involved in the anesthesia care of the subject</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure change</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparision of Systolic blood pressure changes alfentanil vs placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure change</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparison of diastolic blood pressure change alfentanil vs placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparison of heart rate change alfentanil vs placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antihypertensive medication use</measure>
    <time_frame>90 minutes</time_frame>
    <description>comparison of amounts of medications needed to treat blood pressure between the 2 groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Electroconvulsive Therapy</condition>
  <arm_group>
    <arm_group_label>Alfentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfentanil</intervention_name>
    <description>Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
    <arm_group_label>Alfentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; /=18 years

          -  Males or females

          -  Anticipating electroconvulsive therapy to treat refractory depressive disorder

        Exclusion Criteria:

          -  Under the age of 18

          -  Allergy to alfentanil

          -  Allergy to other standard anesthetic medications utilized in the course of ECT
             (glycopyrrolate, methohexital, and succinylcholine)

          -  History of malignant hyperthermia

          -  History of severe airway obstruction, bronchospasm or laryngospasm

          -  History of recent myocardial infarction, ventricular arrhythmia

          -  Adverse reaction to ECT requiring premedication with lidocaine or atropine

          -  Non-English speaking

          -  Patients unable to consent for themselves

          -  Current pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quinn McCutchen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quinn McCutchen, MD</last_name>
    <phone>336-716-4498</phone>
    <email>tmccutch@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Predrag Gligorovic, MD</last_name>
    <email>pgligoro@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quinn McCutchen, MD</last_name>
      <phone>336-716-4498</phone>
      <email>tmccutch@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Predaq Gligorovic, MD</last_name>
      <email>pgligoro@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Kimball, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

